Issue Date: January 15, 2007
Inex, Alnylam form technology alliance
Inex Pharmaceuticals has granted Alnylam an exclusive license to liposomal delivery technology for RNAi therapeutics. In exchange, Inex will receive $8 million in cash or stock and $4 million in R&D funding over the next two years. Inex will manufacture any drugs that come out of the collaboration, using $5 million from Alnylam for any needed equipment. Inex will also receive exclusive access to Alnylam's intellectual property related to the development of immune stimulatory oligonucleotides that do not act on an RNAi pathway.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society